Key2Brain and OliX Pharmaceuticals Enter a Strategic Evaluation and Option Agreement to Advance CNS-Targeted siRNA Delivery
Joint research to develop CNS-targeted siRNAs using Key2Brain’s TfR-targeted BBB shuttle, with an option for a global exclusive license to a CNS disease target
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders